Medicon Valley Alliance, together with Bacthera, have the pleasure to invite you to the Medicon Valley Alliance Microbiome Network meeting on 9th of February, 2022 in Copenhagen.
Live biotherapeutic products (LBPs) are living microorganisms administered therapeutically and the human microbiome is an increasingly important avenue of health research. Today, we know that the microbiome plays a crucial role in the involvement of many diseases from gastrointestinal infections and oncology disorders to systemic inflammatory diseases and skin-related conditions. With this relatively new field of science there are some evident challenges when it comes to practical aspects of manufacturing such as process development and scaling up for commercial manufacturing. Organisations operating within the LBP-industry also needs to adhere to specific regulatory requirements for development and manufacturing of LBP, much of which is still unclear today.
The network meeting will focus on strategies and processes for developing and manufacturing of Live Biotherapeutic Products (LBPs). In the meeting various experts will provide their insights addressing practical aspects of manufacturing and the complex regulatory environment as well as give examples from companies sharing their experiences of developing LBPs.
| Date: | Wednesday 9th of February |
| Time: | 14.30 – 18.00 |
| Venue: | Medicon Valley Alliance, Auditorium, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen |
| Host: | Bacthera |
Program:
| 14.30 – 15.00 | Arrival – registration and networking |
| 15.00 – 15.10 | Welcome and introduction by MVA and Bacthera Anette Steenberg, CEO, Medicon Valley Alliance Felix Faupel, Chief Commercial Officer, Bacthera |
| 15.10 – 15.30 | Advance your live biotherapeutic products from early discovery to manufacturing Wendy Ossieur, Head of Development, Bacthera |
| 15.30 – 15.50 | Navigating the regulatory framework of LBPs from discovery through each stage of development Clara Desvignes, Senior Regulatory Scientist, IWA Consulting / Voisin Consulting Life Sciences |
| 15.50 – 16.10 | Manufacturing considerations when developing an LBP Susanne Kammler, Project Manager, DTU Biosustain |
| 16.10 – 16.30 | Break |
| 16.30 – 16.50 | Emilimogene sigulactibac – currently developed in two formulations for three medical indications Evelina Vågesjö, CEO and Cofounder, Ilya Pharma |
| 16.50 – 17.10 | Clinical perspectives Andreas Munk Petersen, Chief physician, Hvidovre Hospital |
| 17.10 – 17.30 | Discussions and Q&A All speakers and lead by Bacthera |
| 17.30 – 18.00 |
Networking and refreshments |
Deadline for registration is 4th of February, 2022.
The Network
The MVA Microbiome Network is a professional network for Medicon Valley Alliance members from industry, academia and health care sector with interest in the Microbiome field, including drug discovery, nutrition and probiotic development. Our ambition with the MVA Microbiome Network is to create opportunities for microbiome researchers from industry, academia, and health care to meet and collaborate. Joining the network is free of charge but is limited to Medicon Valley Alliance members. However, non-member organizations and companies are welcome to attend one network event to evaluate if joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the microbiome network.
For more information please contact Sofia Norås sn@mva.org
| Host of the event | |
 |
| In Collaboration with | ||
|
|
 |
 |
